Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cross Country Healthcare (CCRN) EBITDA (2016 - 2025)

Historic EBITDA for Cross Country Healthcare (CCRN) over the last 17 years, with Q3 2025 value amounting to -$4.9 million.

  • Cross Country Healthcare's EBITDA fell 29077.35% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.8 million, marking a year-over-year decrease of 79394.8%. This contributed to the annual value of -$14.6 million for FY2024, which is 12011.76% down from last year.
  • Latest data reveals that Cross Country Healthcare reported EBITDA of -$4.9 million as of Q3 2025, which was down 29077.35% from -$6.7 million recorded in Q2 2025.
  • In the past 5 years, Cross Country Healthcare's EBITDA registered a high of $77.6 million during Q4 2021, and its lowest value of -$16.1 million during Q2 2024.
  • Moreover, its 5-year median value for EBITDA was $12.8 million (2023), whereas its average is $19.2 million.
  • In the last 5 years, Cross Country Healthcare's EBITDA skyrocketed by 624986.88% in 2021 and then crashed by 29077.35% in 2025.
  • Quarter analysis of 5 years shows Cross Country Healthcare's EBITDA stood at $77.6 million in 2021, then plummeted by 53.22% to $36.3 million in 2022, then plummeted by 75.08% to $9.0 million in 2023, then plummeted by 141.97% to -$3.8 million in 2024, then dropped by 27.97% to -$4.9 million in 2025.
  • Its last three reported values are -$4.9 million in Q3 2025, -$6.7 million for Q2 2025, and -$485000.0 during Q1 2025.